<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189693</url>
  </required_header>
  <id_info>
    <org_study_id>212006</org_study_id>
    <nct_id>NCT03189693</nct_id>
  </id_info>
  <brief_title>Paravertebral Block for Pain Management After Appendectomy</brief_title>
  <official_title>Paravertebral Block for Postoperative Pain Management in Adult Patients Undergoing Appendectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makassed General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makassed General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paravertebral Block (PVB) was shown to be a successful and useful technique of anesthesia and&#xD;
      analgesia. Its effect was evident in thoracic and abdominal surgeries. In the setting of&#xD;
      appendectomy, somatic PVB has been used for pediatric patients. It was shown to decrease&#xD;
      opioid consumption and provide prolonged pain relief. Hence, it would be beneficial to&#xD;
      examine the analgesic effect of PVB on appendectomy in adult patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing appendectomy will be randomly allocated into two equal groups using the&#xD;
      sealed envelope technique. All patients will receive general anesthesia (GA). Patients in&#xD;
      group I will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture,&#xD;
      while patients in Group II will receive placebo.&#xD;
&#xD;
      Paravertebral Block Technique Unilateral right side nerve stimulator-guided PVB is performed&#xD;
      while patients are in the left lateral decubitis position. The appropriate levels for the PVB&#xD;
      are determined by palpation of the spinous processes. An intervertebral line is drawn at the&#xD;
      appropriate levels and the injection site is marked 2.5 cm lateral to the midline. After&#xD;
      aseptic preparation of the skin, 1 mL 1% lidocaine is infiltrated at the injection sites. A&#xD;
      21-G nerve stimulation needle (Stimuplex; B. Braun, Melsungen, Germany) is advanced 1-2 cm&#xD;
      perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely&#xD;
      watching for contractions of the abdominal muscles. The tip of the needle is adjusted to&#xD;
      maintain muscle contractions while reducing the stimulating current to approximately 0.5-0.6&#xD;
      mA.&#xD;
&#xD;
      4 mL of the local anaesthetic mixture is injected at each injection site. Each 20 mL of the&#xD;
      local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine&#xD;
      5µg/mL and 4 mL bupivacaine 0.5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>The quantity of analgesics consumed will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemodynamic stability measured through mean arterial pressure (MAP).</measure>
    <time_frame>Approximately 1 hour</time_frame>
    <description>Intraoperative hemodynamic stability measured through mean arterial pressure (MAP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Reduce Pain After Appendectomy</condition>
  <arm_group>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PVB</intervention_name>
    <description>nerve stimulator-guided PVB will be performed at two levels</description>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>nerve stimulator-guided PVB containing placebo will be performed at two levels</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GA</intervention_name>
    <description>All patients will receive general anesthesia.</description>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anesthetic injections</intervention_name>
    <description>4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.</description>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older than 18 years&#xD;
&#xD;
          -  Scheduled to undergo appendectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiac disease,&#xD;
&#xD;
          -  developmental delay,&#xD;
&#xD;
          -  neurologic deficit,&#xD;
&#xD;
          -  allergies to any of the drugs routinely used in anesthesia management.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zoher Naja, MD</last_name>
    <phone>+9611636000</phone>
    <phone_ext>6941</phone_ext>
    <email>zouhnaja@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Makassed General Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoher Naja, MD</last_name>
      <phone>+9611636000</phone>
      <phone_ext>6941</phone_ext>
      <email>zouhnaja@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makassed General Hospital</investigator_affiliation>
    <investigator_full_name>Zoher Naja</investigator_full_name>
    <investigator_title>Chairperson of Anesthesia and Pain Management Department</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

